Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Haemophilus b conjugate vaccine tetanus toxoid conjugate
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Hiberix is a brand name for the Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate), a sterile, lyophilized powder reconstituted with saline for intramuscular injection. It contains purified capsular polysaccharide (polyribosyl-ribitol-phosphate [PRP]) from *Haemophilus influenzae* type b covalently bound to tetanus toxoid as a carrier protein. The primary indication is active immunization for the prevention of invasive disease caused by *Haemophilus influenzae* type b in children aged 6 weeks through 4 years (prior to their fifth birthday). The mechanism of action involves stimulating the immune system to produce antibodies against the PRP antigen, conferring protection against invasive Hib disease such as meningitis and sepsis[1][2][3][4][6].
- Brand names
- Hiberix
- Other names
- haemophilus b conjugate vaccine tetanus toxoid conjugatePRP-T vaccineHib vaccine
02
Targets
TT (Tetanus toxoid)
Beyond the preview
Go deeper on Haemophilus b conjugate vaccine tetanus toxoid conjugate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Haemophilus b conjugate vaccine tetanus toxoid conjugate.